A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

NCT01963715 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Positive Solid Tumors

Interventions

DRUG: IMGN289

Sponsor

ImmunoGen, Inc.